Study urging stakeholders to prioritize evidence-based policies and accessible treatments.
In a stunning revelation that challenges the prevailing narrative on COVID-19 treatments, new research published in the journal BMC Cardiovascular Disorders has definitively debunked concerns over the cardiac safety of Hydroxychloroquine paired with Azithromycin, Vitamin C, Vitamin D, and Zinc (HAZDPac). The ProgenaBiome study, conducted by a team of esteemed researchers including Sabine Hazan, Adriana C. Vidal, Nicolas Hulscher, Amelia Goudzwaard, Peter A. McCullough, and Alon A. Steinberg, provides crucial evidence that this combination therapy does not pose significant cardiac risks.
The present study, a Phase II Double-Blind Randomized Placebo-Controlled Trial, meticulously monitored 83 critically ill COVID-19 patients over a 10-day period. Patients receiving HAZDPac treatment showed no significant prolongation of the QTc interval compared to those on placebo. This finding is particularly significant because concerns over QTc interval prolongation have been a major obstacle in the use of Hydroxychloroquine for COVID-19 treatment.
The research design employed continuous EKG monitoring, enabling the team to gather highly accurate data. Utilizing two-sample t-tests, the researchers analyzed QTc intervals recorded from patients in the treatment group and those on placebo, with no significant differences observed. The study's conclusion is unequivocal: HAZDPac, a potent combination therapy, remains a safe and viable option for treating COVID-19, and its use does not lead to cardiac complications.
The findings are particularly noteworthy in light of the ongoing ethical debates surrounding the suppression of alternative COVID-19 treatments. One such controversial episode involves the retraction of a landmark study on Hydroxychloroquine and Azithromycin published by the same research team. This study had been widely cited by 6,713 scientists and researchers over four years before being unjustly removed from circulation. Such retraction raises serious questions about the integrity of scientific inquiry and the motivations behind such actions.
The retraction, dubbed an act of "unethical suppression" by the research community, is seen as part of a broader strategy by biopharmaceutical interests to prioritize profit over public health. "The Biopharmaceutical Complex," as some critics have called it, is accused of systematically downplaying or censoring evidence that might support the use of cheaper, safer, and more accessible treatments like Hydroxychloroquine. The smear campaign against HCQ, for instance, led to publications claiming that HCQ caused 17,000 deaths. This was exposed as fraud. This strategy made way for the promotion of more expensive mRNA vaccines and remdesivir, pushed onto patients under emergency use authorization.
Despite the significant challenges faced, the authors of this study remain steadfast in their commitment to scientific truth and public health. "We will continue to conduct, support, and disseminate high-quality research," stated Professor Peter A. McCullough, a key figure in the research community. "It is our duty to uphold scientific integrity and ensure that effective treatments reach those who need them."